L
Lesley Seymour
Researcher at Queen's University
Publications - 246
Citations - 28587
Lesley Seymour is an academic researcher from Queen's University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 62, co-authored 230 publications receiving 25595 citations. Previous affiliations of Lesley Seymour include Ontario Institute for Cancer Research & University of Turin.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Jean Pierre Pignon,Hélène Tribodet,Giorgio V. Scagliotti,Jean-Yves Douillard,Frances A. Shepherd,Richard J. Stephens,Ariane Dunant,Valter Torri,Rafael Rosell,Lesley Seymour,Stephen G. Spiro,Estelle Rolland,Roldano Fossati,Delphine Aubert,Keyue Ding,David A. Waller,Thierry Le Chevalier +16 more
TL;DR: Postoperative cisplatin-based chemotherapy significantly improves survival in patients with non-small-cell lung cancer (NSCLC).
Journal ArticleDOI
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao,Akira Sakurada,Jean-Claude Cutz,Jean-Claude Cutz,Chang-Qi Zhu,Chang-Qi Zhu,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Jeremy A. Squire,Jeremy A. Squire,Ian A. J. Lorimer,Tong Zhang,Tong Zhang,Ni Liu,Ni Liu,Manijeh Daneshmand,Paula Marrano,Paula Marrano,Gilda da Cunha Santos,Gilda da Cunha Santos,Alain E. Lagarde,Frank C. Richardson,Lesley Seymour,Marlo Whitehead,Keyue Ding,Joseph L. Pater,Frances A. Shepherd,Frances A. Shepherd +27 more
TL;DR: Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.
Journal ArticleDOI
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more
TL;DR: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Journal ArticleDOI
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour,Jan Bogaerts,Andrea Marie Perrone,Robert Ford,Lawrence H. Schwartz,Lawrence H. Schwartz,Sumithra J. Mandrekar,Nan Lin,Saskia Litière,Janet Dancey,Alice P. Chen,F. Stephen Hodi,Patrick Therasse,Otto S. Hoekstra,Lalitha K. Shankar,Jedd D. Wolchok,Marcus Ballinger,Marcus Ballinger,Marcus Ballinger,Caroline Caramella,Elisabeth G.E. de Vries +20 more
TL;DR: This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used and defines the minimum datapoints required from future trials to facilitate the compilation of a data warehouse to later validate iRECIST.